Risk Assessment for Continuous Flow Left Ventricular Assist Devices: Does the Destination Therapy Risk Score Work?
Authors:
- Jeffrey J. TeutebergJTJeffrey J. Teuteberg
- Greg A. EwaldGEGreg A. Ewald
- Robert M. AdamsonRARobert M. Adamson
- Katherine LietzKLKatherine Lietz
- Leslie W. MillerLMLeslie W. Miller
- Antone J. TatoolesATAntone J. Tatooles
- Robert L. KormosRKRobert L. Kormos
- Kartik S. SundareswaranKSKartik S. Sundareswaran
- David J. FarrarDFDavid J. Farrar
- Joseph G. RogersJRJoseph G. Rogers
Abstract
No abstract availableKeywords
Funding Information
- Thoratec Corporation
- HeartWare
This publication has 17 references indexed in Scilit:
- Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical TrialThe Annals of Thoracic Surgery, 2011
- Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classificationThe Journal of Heart and Lung Transplantation, 2011
- Third INTERMACS Annual Report: The evolution of destination therapy in the United StatesThe Journal of Heart and Lung Transplantation, 2011
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceNew England Journal of Medicine, 2009
- Extended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist DeviceJACC, 2009
- Risk Score Derived from Pre-operative Data Analysis Predicts the Need for Biventricular Mechanical Circulatory SupportThe Journal of Heart and Lung Transplantation, 2008
- Use of a Continuous-Flow Device in Patients Awaiting Heart TransplantationNew England Journal of Medicine, 2007
- Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH EraCirculation, 2007
- The Seattle Heart Failure ModelCirculation, 2006
- Development and Prospective Validation of a Clinical Index to Predict Survival in Ambulatory Patients Referred for Cardiac Transplant EvaluationCirculation, 1997